Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
BioCryst & Idera Announce Merger to Combine Capabilities January 29, 2018
BioCryst Pharmaceuticals, Inc. and Idera Pharmaceuticals, Inc. recently announced they have signed a definitive merger agreement to form a new...SPECIAL FEATURE - Analytical Testing - Contractors Take on the Challenge of Complex Molecules January 9, 2018
Contributor Cindy H. Dubin highlights some of the analytical testing services that leading contractors offer aimed at the increasing complexities of today’s pharmaceutical pipelines.
FOAMED SILICONE - Molded Porous Silicone for Delivery of Macromolecules & Low-Solubility APIs January 9, 2018
James Arps, PhD, and Matt Petersen, PhD, investigate how foamed silicone is capable of sustained, controlled elution of hydrophobic small molecule and large macromolecular payloads.
pSivida & Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug October 17, 2017
pSivida Corp., a leader in the development of sustained release drug products and technologies, and Nicox S.A., the international ophthalmic...ADVANCED DELIVERY DEVICES - The Staked Needle Pre-Filled Syringe: Benefits, Conventional Limitations & a New Approach October 2, 2017
Horst Koller and John A. Merhige, MEM, say the advantages of a Staked Needle Pre-Filled Syringe are clear and well documented, but significant risks remain. A new alternative is now available that addresses the known challenges and adds critical usability and safety features while preserving existing components and processes.
Inspyr Therapeutics & Lewis and Clark Pharmaceuticals Complete Merger September 18, 2017
Inspyr Therapeutics and Lewis and Clark Pharmaceuticals recently announced the successful completion of a merger to create an integrated biotechnology...SPECIAL FEATURE - Injectable Drug Delivery: New Technologies Deliver Biologics & Differentiate Brands September 12, 2017
Contributor Cindy H. Dubin reports on a segment of the drug delivery industry that will see its market revenue double in just 5 years in response to a growing need to deliver highly viscous, high-volume drugs.
Genmab & Seattle Genetics to Co-Develop Tisotumab Vedotin for Solid Tumors September 5, 2017
Genmab A/S and Seattle Genetics, Inc. recently announced that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin....Rexahn Pharmaceuticals Receives New US Patent September 5, 2017
Rexahn Pharmaceuticals, Inc. recently announced that the United States Patent and Trademark Office has issued US Patent No. 9,744,167, Nanoparticulate...Enteris Biopharma Doses First Woman in Phase 2a Clinical Trial August 28, 2017
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, recently announced the first...Aptevo Therapeutics Highlights ADAPTIR™ Protein Therapeutic Platform June 12, 2017
Aptevo Therapeutics Inc. recently announced that aspects of its ADAPTIR protein therapeutic platform were showcased recently at the Americas Antibody...SPECIAL FEATURE - Wanted: New Excipients to Meet the Demands of a Challenging Industry June 1, 2017
Contributor Cindy H. Dubin recently spoke with some of the leading excipient innovators to find out what types of excipients they are developing, the advantages they offer to formulations, and where they see the industry focusing throughout the next few years.
EXECUTIVE INTERVIEW - Oasmia Pharmaceutical: Commercializing Technologies While Pursuing the US Market May 1, 2017
Julian Aleksov, Executive Chairman of Oasmia Pharmaceutical, discusses his company’s efforts to enter the US market, its strategy to increase commercial adoption, and why it believes its underlying drug delivery system technology is significant not only within the oncology sector, but the entire pharmaceutical industry.
GNT Biotech & Medicals Corporation to Begin Phase III Clinical Trial April 24, 2017
GNT Biotech & Medicals Co., Ltd. recently announced that the anticancer drug Chidamide (HBI-8000), an epigenetic regulator developed by Chipscreen...UroGen Pharma Announces Enrollment of First Patient in Phase III Clinical Trial April 10, 2017
UroGen Pharma Ltd. recently announced the first patient has been enrolled in the OLYMPUS trial, an open-label, single-arm pivotal Phase...ANTIMICROBIAL RESISTANCE - MGB: The Minor Groove Binder April 3, 2017
Dawn A. Firmin, MSc, PhD, explains how MGB has dedicated its focus to the development of a new class of small molecules, with specific antibacterial activity against susceptible and resistant bacteria.
ANTIMICROBIAL LIPIDS - Attenuating the Use of Medically Important Antimicrobial Drugs in Food-Producing Animals: What Role Can cGMP Lipids Play? April 3, 2017
Ryan Littich, PhD, highlights some of the most significant, pathogen-borne diseases relevant to food-producing animals and reviews the antimicrobial properties intrinsic to midchain triglyceride lipolysis products.
Aclaris Therapeutics Submits NDA for Seborrheic Keratosis March 6, 2017
Aclaris Therapeutics, Inc. recently announced it has submitted a New Drug Application (NDA) to the US FDA for A-101 40%...AAV VECTOR MANUFACTURING - Challenges & Opportunities in the Manufacturing of AAV Vectors Used in the Delivery of Gene Therapy Treatments February 28, 2017
Daniel C. Smith, PhD, indicates there remains a clear need for improved process productivities, and the need to develop manufacturing processes that can be applied to a wide number of AAV-based viral vector therapeutic candidates.
SPECIAL FEATURE - Bioavailability & Solubility: New Approaches to Enhance Drug Performance February 27, 2017
Contributor Cindy H. Dubin highlights many of the latest techniques to enhance bioavailability and solubility, how to determine the right technique for your compound, and how some companies are realizing faster time to market as a result.
Company Profiles
Lyophilization Technology, Inc.
Lyophilization Technology, Inc. 30 Indian Drive Ivyland, PA 18974-1431 T: (215) 396-8373 F: (215) 396-8375 E: inquiry@lyo-t.com W: www.lyotechnology.com WHO...DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products
Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.
